Runjia Li, PhD

Eli Lilly and Company
Indianapolis, Indiana, United States

Disclosure information not submitted.

Presentation(s):

• MON-738 - Orforglipron and the 10-year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes: A Post Hoc Analysis from the ATTAIN-1 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT